This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Tandem Diabetes Signs as an Insulin Pump Vendor in Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Tandem's Global Growth a Boost, Operating Losses a Bane
by Zacks Equity Research
Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.
Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Tandem Diabetes Care (TNDM)
by Kevin Cook
FDA approval of its latest smart insulin pump has revived investor faith in shares that once traded above $300
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
4 Dark Horse Stocks Ready to Explode in 2019
by Tirthankar Chakraborty
We highlight a few dark horse stocks that could come up with better-than-expected results this year and won't burn a hole in your pocket
Is Tandem Diabetes Care (TNDM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TNDM) Outperforming Other Medical Stocks This Year?
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
Best Sector of 2018 and its Hit ETFs & Stocks
by Sweta Killa
Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.
Implied Volatility Surging for Tandem Diabetes (TNDM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
Why Is Tandem Diabetes (TNDM) Down 9.4% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat
by Zacks Equity Research
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.
Tandem Diabetes (TNDM) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).
Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options
by Zacks Equity Research
Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Is Tandem Diabetes Care (TNDM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TNDM) Outperforming Other Medical Stocks This Year?
Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Tandem Diabetes Care (TNDM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.